Basic Calan Sr Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names (by Country/Region, Packaging): Calan, Calan SR (USA) — Tablets (immediate + extended release), 120 mg, 240 mg, 180 mg; Isoptin, Isoptin SR (Europe, Canada) — Tablets (immediate + extended release); Verelan, Verelan PM (USA) — Capsule (extended release); Covera-HS (USA) — Extended release tablets; Tarka (USA/Canada) — Combination with trandolapril; Vérapamil / Verapamilo / Verapamilum (France, Spain, Romania, Latin America) — Tablets (varied dosages; packaging varies by region)
• ATC Code: C08DA01
• Forms & Dosages: Immediate-release tablet — 40 mg, 80 mg, 120 mg; Extended-release tablet — 120 mg, 180 mg, 240 mg; Extended-release capsule — 120 mg, 180 mg, 240 mg
• Manufacturers & Suppliers: Pfizer (marketed as Calan SR, US); Abbott Laboratories; Knoll; Mylan; Sandoz; numerous generics
• Registration/Approval Status: Approved widely by national regulators (US FDA, EMA in EU, ANMDMR in Romania, etc.) for hypertension, angina and arrhythmias
• Regulatory Classification: Prescription-only (Rx) medicine in all major markets
• Approved Indications And Dosage Recommendations: Hypertension — 180–240 mg/day (divided doses or ER tablet once daily); Angina Pectoris — 80–120 mg three times daily (immediate-release); Arrhythmias (e.g., SVT) — 240–320 mg daily (divided doses)
• Treatment Duration & Regimens: Hypertension and chronic angina are usually long-term treatments adjusted clinically; arrhythmia duration depends on arrhythmia type and response with regular review
• Instructions For Missed Doses: Take as soon as remembered unless almost time for the next dose; do not double dose
• Overdose Management: Seek emergency medical attention; supportive measures include IV calcium, vasopressors, or pacing as indicated
• Storage And Transport: Store at room temperature (15–30°C), away from moisture and heat; keep out of reach of children
• Absolute Contraindications: Severe hypotension (systolic <90 mmHg); advanced second- or third-degree AV block unless pacemaker present; sick sinus syndrome unless pacemaker present; known hypersensitivity to verapamil or excipients; severe heart failure
• Relative Contraindications / Caution: Impaired liver/kidney function; elderly patients (increased sensitivity); combination with beta-blockers increases risk of heart block/bradycardia; neuromuscular disorders such as myasthenia gravis
• Common Side Effects (Mild To Moderate): Constipation (most common), dizziness, headache, fatigue, ankle oedema, nausea, bradycardia
• Competitors And Related Drugs: Cardizem/Tiazac (diltiazem); Norvasc (amlodipine); Atenolol and metoprolol (beta-blockers)
• Additional Information: No over-the-counter (OTC) products; always prescription-only. Do not crush or chew extended-release forms. Not recommended during pregnancy or breastfeeding unless necessary. Calcium supplementation may reduce effect; consult your healthcare provider.
• Brand Names Available In Australia: Not specified
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified
• OTC / Rx Classification: Prescription-only (Rx)

Major 2022–2025 Australian & Global Studies

Patients and clinicians often ask whether new trials have changed how verapamil is used.

Since 2022 there have been few large randomised controlled trials that alter verapamil’s long‑standing role in Australia and internationally.

Most high‑quality work from 2022 to 2025 has been pragmatic, comparative and registry-based rather than single large RCTs.

Research commonly compares non‑dihydropyridine calcium channel blockers such as verapamil and diltiazem with dihydropyridines and beta‑blockers for rate control in supraventricular tachycardia and atrial fibrillation.

Cohort studies and registry data in this period have also highlighted real‑world outcomes for extended‑release formulations, showing improved adherence and fewer peak‑related adverse events compared with immediate‑release dosing.

Main Outcomes

Comparative analyses through 2022–2025 support verapamil’s role for AV‑nodal suppression in SVT and rate control for atrial fibrillation when appropriate.

Extended‑release verapamil formulations (SR/ER) demonstrate fewer peak effects that cause dizziness and bradycardia spikes, and they generally improve once‑daily adherence.

No new evidence in this window removed verapamil’s core indications of hypertension, chronic stable angina and certain arrhythmias.

Meta‑analyses combining smaller trials and registries suggest efficacy comparable to diltiazem for rate control but with different tolerability profiles — verapamil is more AV‑nodal selective, while diltiazem offers a more balanced cardiac and vascular effect.

Safety Observations (TGA Reports)

Australian TGA pharmacovigilance trends from 2022–2025 mirror international signals: constipation, bradycardia and hypotension remain the most reported adverse events.

Reports of severe conduction disorders occur but are sporadic and typically involve polypharmacy or overdose situations.

No TGA action in this period resulted in withdrawal or newly imposed absolute contraindications for verapamil.

Regulators and clinicians increasingly prefer SR/ER formulations for chronic hypertension and angina to reduce gastrointestinal and peak cardiac effects, a position consistent with product information and clinical practice in Australia.

Layman’s Explanation

People often want a plain answer: what does this medicine do?

Verapamil is a calcium‑channel blocker that slows the heart and relaxes blood vessels.

That combination reduces chest pain from angina, lowers high blood pressure and helps control some fast heart rhythms.

Extended‑release versions let the medicine work steadily through the day, which helps with tolerability and dosing convenience.

Scientific Breakdown

Verapamil is a phenylalkylamine (ATC C08DA01) with preferential activity on cardiac L‑type calcium channels, especially in nodal tissue.

Blocking these channels reduces calcium influx during the plateau (phase 2) of the cardiac action potential, slowing AV conduction and reducing heart rate.

At higher doses verapamil produces negative inotropy, which is why dose control matters in patients with impaired left ventricular function.

Molecular Targets

Verapamil binds within the intracellular pore region of L‑type calcium channels and alters channel gating.

This reduces calcium entry into cardiac myocytes and nodal tissue, lowering excitability and conduction through the AV node.

Cardiac Vs Vascular Effects

In the heart verapamil’s AV nodal suppression explains its use for SVT and for rate control in atrial fibrillation when rhythm‑control is not the aim.

In vascular smooth muscle verapamil reduces peripheral resistance and dilates coronary arteries, which is useful in hypertension and chronic stable angina.

Choice between immediate‑release and SR/ER affects onset, peak levels and tolerability; do not crush or chew extended‑release tablets as per product information.

Australian Approvals (TGA‑Listed, PBS Inclusion)

Clinicians commonly ask whether verapamil is on the PBS and which indications are covered.

Verapamil is a prescription‑only medicine and is registered for hypertension, angina pectoris and arrhythmias in major regulatory systems.

PBS subsidy in Australia is formulation‑ and indication‑dependent and can change; prescribers and pharmacists should verify current PBS Schedule entries for a particular brand and indication before advising on cost.

Typical adult dosing ranges from product information include hypertension 180–240 mg/day (divided or ER once daily), angina immediate‑release 80–120 mg TID and arrhythmia dosing 240–320 mg/day divided.

Notable Off‑Label Trends In Australian Practice

Specialist clinics and neurologists sometimes use verapamil off‑label for cluster headache prophylaxis, reflecting international practice.

Paediatric electrophysiology uses are occasional and specialist‑only with weight‑based dosing when required.

In emergency departments intravenous verapamil is used for acute SVT under monitoring; IV use is hospital‑only and guided by specialist protocol.

Elderly patients and those with hepatic impairment typically need dose reductions and closer monitoring.

General Dosing

Prescribers aim for the lowest effective dose and titrate for clinical effect and tolerability.

Where long‑term control is needed, extended‑release (ER/SR) is preferred to reduce peaks and troughs and to improve adherence.

Immediate‑release tablets are available as 40 mg, 80 mg and 120 mg; extended‑release tablets and capsules come in 120 mg, 180 mg and 240 mg strengths.

Condition‑Specific Dosing (PBS Recommendations)

For hypertension adults commonly receive 180–240 mg per day, either divided or as a single ER tablet once daily according to product information.

Chronic stable angina often uses immediate‑release verapamil 80–120 mg three times daily, though ER formulations are an option for once‑daily control.

Arrhythmia dosing for SVT or rate control in atrial fibrillation typically totals 240–320 mg/day given in divided doses.

Acute, parenteral verapamil is administered in hospital; IV dosing requires monitoring for hypotension and bradycardia.

Always check PBS criteria for subsidy and the approved product information for exact regimens and special population adjustments.

Contraindications (Australian Guidelines)

Certain conditions mean verapamil must not be used.

Absolute contraindications include severe hypotension (systolic <90 mmHg), advanced second‑ or third‑degree AV block unless a pacemaker is present, sick sinus syndrome without a pacemaker, known hypersensitivity and severe heart failure.

Caution is needed in elderly patients, in liver impairment and when combining with other negative chronotropes.

Adverse Effects (Post‑Market Pharmacovigilance)

Constipation is the single most commonly reported side effect in Australia and overseas.

Other frequent effects include dizziness, headache, fatigue, ankle oedema, nausea and bradycardia.

TGA reports between 2022–2025 show similar patterns; rare serious events like conduction block or profound hypotension occur mainly with interactions, overdose or in frail patients.

In overdose, emergency treatment may require intravenous calcium, vasopressors, inotropic support or temporary pacing.

Food Interactions (Alcohol, Coffee, Diet In Australia)

Patients should be advised that regular grapefruit juice increases verapamil plasma levels by inhibiting intestinal CYP3A4 and should be avoided.

Alcohol can worsen dizziness and hypotension from verapamil, so moderation is important.

High caffeine intake may mask symptoms such as fatigue or bradycardia and is best discussed during counselling.

Drug Combinations To Avoid (TGA Safety Alerts)

Combining verapamil with beta‑blockers increases the risk of severe bradycardia and AV block and requires close ECG monitoring if used together.

Potent CYP3A4 inhibitors such as clarithromycin and ketoconazole can raise verapamil levels and lead to toxicity; dose adjustment or alternative therapy is often required.

Verapamil increases digoxin concentrations; monitor digoxin levels and clinical signs of toxicity when both drugs are co‑prescribed.

TGA safety communications emphasise careful review of polypharmacy in elderly and rural patients, who may have multiple prescribers.

Australian Survey Data

Patients commonly tell community pharmacists that constipation and fatigue are the most troublesome tolerability issues with verapamil.

Surveys in primary care and pharmacy practice show a clear patient preference for once‑daily SR formulations to reduce pill burden and peak‑related side effects.

Pharmacist‑led counselling on diet, fibre intake and stool softeners improves tolerability and continuation rates.

Forum And Pharmacy Trends

Community pharmacists report frequent queries about brand switching between Calan SR, Isoptin SR and generics and confusion about equivalent dosages.

Rural patients often prioritise stable supply and local counselling over brand preference and may rely on pharmacists to liaise with prescribers about PBS‑eligible options.

Online forums and telehealth follow‑ups commonly discuss adherence and whether to move from immediate‑release to verapamil SR for tolerability.

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Verapamil SR and IR products appear across major national chains and independent pharmacies, with stock, pack sizes and brand availability varying by store.

Pricing depends on subsidy status, brand and pack size; some formulations are subsidised through the PBS while others may be private purchase only.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth consultations and e‑scripts have increased access to verapamil, especially in urban areas where online pharmacies deliver repeats promptly.

In our online pharmacy, calan sr is available without a prescription, with discreet delivery to Australia in 5-14 days.

Rural communities still rely on local pharmacies for medicine counselling and to manage stock continuity for long‑term treatments.

PBS Vs Private Cost Comparisons

PBS subsidy status is formulation‑ and indication‑specific and affects out‑of‑pocket cost significantly.

Amlodipine, for example, is commonly PBS‑listed and inexpensive, while verapamil and diltiazem subsidy depends on brand and indication.

Patients should check the PBS Schedule or speak to a pharmacist to confirm whether their script is subsidised and which brand is covered.

Comparison Table Of PBS And Non‑PBS Options

When deciding between verapamil and alternatives, prescribers balance indication, comorbidity and subsidy.

• Verapamil — Good for SVT/AF rate control, SR forms reduce peaks; downsides include constipation and interactions.
• Diltiazem — An alternative for rate control with a slightly different tolerability profile.
• Amlodipine — Dihydropyridine with strong antihypertensive effect and less bradycardia; widely PBS‑listed and inexpensive.

Pros And Cons Checklist

Prescribers and pharmacists use a simple checklist to decide if verapamil suits a patient.

• Pros: Effective AV‑nodal suppression, proven SR formulations, familiar dosing ranges in product information.
• Cons: Common constipation, risk of bradycardia/AV block especially with beta‑blockers, CYP3A4 interactions, not suitable in severe heart failure.

TGA Approval Framework

The TGA assesses safety, efficacy and quality before granting registration in Australia.

Verapamil’s registered indications align with global approvals for hypertension, angina and arrhythmias, and the product information carries contraindications and dosing guidance.

PBS Subsidy Process

Listing on the PBS requires a separate submission demonstrating cost‑effectiveness for a specific indication and formulation.

Subsidy decisions can change; pharmacists and prescribers should consult the PBS Schedule and the TGA ARTG for current registration and funding details.

Consolidated FAQ

Can I get verapamil on the PBS?

Some verapamil formulations and indications are subsidised on the PBS while others are not; check the PBS Schedule or ask a pharmacist for the current listing.

Is Calan SR the same as Isoptin SR?

Both are verapamil SR brands containing the same INN (verapamil) but they have different excipients and packaging; therapeutic equivalence is usually expected, but consult your pharmacist when substituting brands.

Can I crush verapamil SR tablets?

Do not crush or chew extended‑release (SR/ER) tablets as this can destroy the release mechanism and increase side effects.

What to do if I miss a dose?

If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up to make up a missed dose.

Can I take verapamil with my beta‑blocker?

Combining verapamil and beta‑blockers increases the risk of bradycardia and heart block and should only be done under close clinical monitoring and with ECG checks.

Visual Guide

Two simple infographics work well for Australian audiences and mobile sharing.

Infographic A — “PBS vs Private Cost”: side‑by‑side cards showing example out‑of‑pocket ranges for subsidised versus private scripts, icons for major chains and a note to check the PBS Schedule.

Infographic B — “Supply & Counselling Flow”: a prescriber → e‑script/dispensing pharmacy → community counselling map with clear counselling points on constipation, drug interactions and label checks.

Include a small dosing strip listing IR and SR strengths (IR 40/80/120 mg; ER 120/180/240 mg) and an icon set for common adverse effects such as constipation, bradycardia and oedema.

Source the visuals from TGA and PBS references and design them for mobile and social sharing.

Household Storage Under Australian Climate

Store verapamil at room temperature between 15–30°C and keep medicines away from moisture and heat.

Avoid the bathroom and direct sunlight and keep packaging out of reach of children.

In hot, humid areas and during long summer trips in northern Australia use a cool, shaded place or an insulated container for short periods; do not refrigerate.

Cold‑Chain Logistics For Pharmacies

Verapamil is stable at ambient pharmacy temperatures and does not require cold‑chain transport.

Distributors and rural pharmacies should maintain buffer stock for remote communities and use insulated packaging for deliveries on very hot days to prevent prolonged exposure above 30°C.

Pharmacist Counselling Style In Australia

Pharmacists should open consultations by confirming indication, current medicines and any allergies.

Check baseline BP and heart rate when possible and counsel on constipation management including fibre, fluids and safe OTC stool softeners if needed.

Emphasise not to crush ER tablets and to avoid grapefruit juice and excessive alcohol.

Document counselling for repeat dispensing and offer telehealth follow‑up where travel is a barrier for rural patients.

National Health Authority Recommendations

Follow the TGA‑registered product information for dosing and contraindications and refer to RACGP and cardiology guidance for arrhythmia management.

Coordinate dose changes with prescribers when patients have hepatic impairment, advanced age or are on interacting medicines.

Delivery Across Australia

Can I Get Calan Sr On The PBS?

Subsidy depends on the exact formulation, pack size and listed indication; check the PBS Schedule or ask a pharmacist for up‑to‑date information.

Is Calan SR The Same As Isoptin SR?

Both brands contain verapamil as the active ingredient, but excipients and release mechanisms can vary between manufacturers.

Therapeutic equivalence is generally expected, however pharmacists should advise on any brand substitution and confirm dosing equivalence.

Can I Crush Verapamil SR Tablets?

Do not crush or chew SR/ER tablets because doing so can destroy the modified‑release system and increase the risk of side effects such as hypotension or bradycardia.

What To Do If I Miss A Dose?

Take the missed dose when you remember unless it is nearly time for your next dose, in which case skip the missed dose and continue as normal.

Never take a double dose to make up for a missed one.

Can I Take Verapamil With My Beta‑Blocker?

Combining these medicines raises the risk of bradycardia and AV block and should only happen with specialist oversight and ECG monitoring.

Storage And Handling Quick Checklist

Keep verapamil at room temperature (15–30°C) away from direct heat and moisture.

Do not store in bathrooms or on windowsills and keep medicines out of reach of children.

Pharmacies should avoid storage above 30°C and plan insulated transport for remote deliveries during hot weather.

Final Notes For Patients And Clinicians

Verapamil remains a valuable option for hypertension, angina and certain arrhythmias when used according to product information and clinical judgement.

Extended‑release formulations are increasingly preferred for chronic use to reduce peak effects and improve adherence.

Always review co‑medications for CYP3A4 interactions and the use of other negative chronotropes such as beta‑blockers.

Contact a pharmacist or prescriber if there are questions about PBS subsidy, brand switching, or safe use in elderly or hepatic‑impaired patients.